PSYCHIATRIC ADVERSE EFFECTS Evidence based on recent studies While GLP-1 RAs have demonstrated potent glucose-lowering effects, their impact on diabetic retinopathy remains incompletely elucidated
After week 24, discontinuation due to side effects dropped to just 4.2%
Mentis N, Vardarli I, Kthe LD, Holst JJ, Deacon CF, Theodorakis M, et al
Eden offers access to GLP-1-based solutions through a subscription service that you can cancel anytime
October 2024: Lilly announces tirzepatide shortage is resolved and the FDA removes tirzepatide from the shortage list
People who are pregnant, planning pregnancy, have certain endocrine cancer histories, have a history of pancreatitis, have gallbladder concerns, take interacting medications, or have other relevant medical conditions should discuss risks and alternatives with a qualified healthcare professional before considering any GLP-1 medication program